Detecting liver scarring in chronic liver disease
Part of Digestive system clinical trials.
This trial looks for better ways to detect liver scarring (fibrosis) in people with long-term liver disease. It may help find problems earlier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a chronic (long-term) liver condition caused by alcohol, fatty liver, viruses, autoimmune issues, blocked bile ducts, or iron overload.
- You cannot have acute (sudden) hepatitis.
- You must be able to safely have a Fibroscan (a special ultrasound for the liver). This means you cannot have fluid in the belly (ascites) or severe heart failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two non-invasive ultrasound methods (EUS-SWQ and FibroScan) with liver biopsy to see how well they detect liver scarring in patients with chronic liver disease. The goal is to improve how doctors diagnose and monitor liver damage from conditions like hepatitis B and fatty liver disease.
This study enrolls people with confirmed fatty liver to help researchers create and validate tests that may estimate liver scarring (fibrosis). It focuses on collecting medical information and verifying the liver condition using lab/scan results, which could help improve future care.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study checks people who are at higher risk for liver scarring by using noninvasive tests. If those tests suggest significant scarring, the study may consider further testing, but not everyone will need a biopsy.
This study compares two non-invasive approaches to diagnose advanced liver scarring in people with non-alcohol-related fatty liver disease (NAFLD). It may help confirm which test strategy finds advanced scarring without needing a biopsy for everyone.
This study tests a way to find liver scarring (fibrosis) early in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. Early detection may help prevent serious liver damage.
Hear when a new Chronic Liver Disease (CLD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.